GMP for Phase 1 Products - Webinar by GlobalCompliancePanel
View: 119
Website http://bit.ly/1ca7yc9 |
Edit Freely
Category Webinar, Health, Medical, Pharma, Clinical
Deadline: September 26, 2013 | Date: September 26, 2013
Venue/Country: USA, U.S.A
Updated: 2013-08-12 16:06:50 (GMT+9)
Call For Papers - CFP
Overview: This presentation will cover the contents of the guidance that was given. FDA has issued as rule that relieves Phase 1 products from complying with the GMP given in 21 CFR 211. At the same time, they ruled that the products must continue to comply with the GMP as given in the Food, Drug, and Cosmetic Act. Guidance was then given to describe these GMP. Areas Covered in the Session:What types of phase 1 products are covered by the rule, and which ones are not.What is the regulatory basis for the rule.A description of what is considered to be the GMP under the Food, Drug, and Cosmetic Act, and how it compares to the GMP given in 21 CFR 211.Who Will Benefit:Quality control and quality assurance workers.Regulatory Affairs personnelProduct development workersPersonnel planning clinical studies.Manufacturing supervisorsSteven S. Kuwahara, Ph.D. is the founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steve has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories .NetZealous LLC,DBA GlobalCompliancePanel 161 Mission Falls Lane,Suite 216, Fremont, CA 94539, USA USA Phone:800-447-9407Fax: 302-288-6884webinars
globalcompliancepanel.com http://www.globalcompliancepanel.com
Event Link - http://bit.ly/1ca7yc9
Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.